Regulus Therapeutics (NASDAQ:RGLS) Earns “Buy” Rating from HC Wainwright

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating reiterated by HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $10.00 price target on the biopharmaceutical company’s stock.

Regulus Therapeutics Stock Performance

Regulus Therapeutics stock opened at $1.27 on Wednesday. Regulus Therapeutics has a twelve month low of $0.83 and a twelve month high of $3.79. The firm has a market cap of $83.19 million, a PE ratio of -1.19 and a beta of 1.58. The firm’s 50 day moving average price is $1.34 and its two-hundred day moving average price is $1.49.

Insider Activity at Regulus Therapeutics

In other Regulus Therapeutics news, CEO Joseph P. Hagan sold 115,290 shares of Regulus Therapeutics stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $145,265.40. Following the transaction, the chief executive officer now directly owns 222,572 shares of the company’s stock, valued at $280,440.72. The trade was a 34.12 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Christopher Ray Aker sold 38,547 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,569.22. Following the transaction, the vice president now owns 54,634 shares in the company, valued at $68,838.84. This represents a 41.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 223,998 shares of company stock valued at $282,237. 4.35% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Regulus Therapeutics

Institutional investors have recently bought and sold shares of the business. Creative Planning acquired a new position in shares of Regulus Therapeutics during the 3rd quarter worth about $26,000. SG Americas Securities LLC acquired a new stake in Regulus Therapeutics during the 3rd quarter worth approximately $33,000. Jane Street Group LLC acquired a new stake in Regulus Therapeutics in the 3rd quarter valued at approximately $46,000. PEAK6 LLC bought a new position in Regulus Therapeutics in the fourth quarter valued at $95,000. Finally, Velan Capital Investment Management LP bought a new stake in Regulus Therapeutics during the 4th quarter worth about $111,000. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.